Publication | Closed Access

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Hematological MalignancyLymphoid NeoplasiaMedicineLong-term Clinical OutcomesImmunologyHematologyPathologyImmunotherapyOncologyRadiation OncologyHealth Sciences